A small working group was convened to discuss some of the broad questions and issues arising from the Phase 1 TGN1412 trial in which participants experienced adverse events.
Status: Completed- You are here:
- Policy
- Overview
- All policy projects
- Testing antibody therapies
Testing antibody therapies
In March 2006, six volunteers taking part in a phase I clinical trial of a monoclonal antibody, TGN1412, experienced severe adverse events. As part of the Academy's on-going work into the research and development of new medicines, a small working group was convened to discuss some of the broad questions and issues arising from the TGN1412 trial. The project was completed within three months; an example of the Academy responding rapidly to an issue of national importance.